BioPharma Innovation & Commercialization
Myron Michael Pyzyk, Principal Consultant
MARENON CONSULTING
Tel./Viber/WhatsApp +1 647-687-7297
E-mail: myron@marenon.com
SKYPE: myron.pyzyk
LinkedIn: http://www.linkedin.com/in/myronpyzyk
PUBLICATIONS
1. Armstrong D, Pare P, Pericak D, Pyzyk M. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopynegative reflux disease. Am J Gastroenterol 2001 Oct;96(10):2849-57.
2. Paré P, Armstrong D, Pericak D, Pyzyk M. Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double-blind comparative study with nizatidine. J Clin Gastroenterol, 2003. 37(2):132-8.
3. Paré P, Meyer F, Armstrong D, Pyzyk M, Pericak D, Goeree R. Validation of the GSFQ, a self-administered symptom frequency questionnaire for patients with gastroesophageal reflux disease. Can J Gastroenterol, 2003. 17(5):307-12.
4. Armstrong D, Kazim F, Gervais M, Pyzyk M. Early relief of upper gastrointestinal dyspeptic symptoms: A survey of empirical therapy with pantoprazole in Canadian clinical practice. Can J Gastroenterol. 2002;16:439-450. Abstract
5. Moldofsky H, Goodacre S, Lue SA, Pyzyk M, Collins S: The prevalence of gastroesophageal reflux disease and sleep-related symptoms. Sleep 1998; 21 (3 Suppl.): 172.
6. Lacourcière Y; Poirier L; Pyzyk M 2.5 and 5 mg cilazapril once-daily in comparison with placebo in hypertension. A comparative study with ambulatory 24-hour monitoring. Cardiology 1993;82 Suppl 2():78-82.
7. Poirier L; Pyzyk M; Provencher P; Lacourcière Y Comparative effects of 2.5 and 5 mg cilazapril versus placebo on daily blood pressure load. American journal of hypertension : journal of the American Society of Hypertension 1991;4(11):913-5.
8. Lacourcière Y; Poirier L; Provencher P; Pyzyk M Antihypertensive effects of cilazapril, 2.5 and 5 mg, once daily versus placebo on ambulatory blood pressure following single- and repeat-dose administration. Journal of cardiovascular pharmacology 1991;18(2):219-23.
